Clinical trial
BGOG-cx1/ENGOT-cx1: "Randomized Double-blind Phase II Study Comparing 3-weekly Carboplatin + Paclitaxel With or Without Concomitant and Maintenance Nintedanib (NINTEDANIB) in Advanced or Recurrent Cervical Carcinoma."
NCT02009579 is registered in ClinicalTrials.gov with Belgian Gynaecological Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- BGOG-cx1/ENGOT-cx1: "Randomized Double-blind Phase II Study Comparing 3-weekly Carboplatin + Paclitaxel With or Without Concomitant and Maintenance Nintedanib (NINTEDANIB) in Advanced or Recurrent Cervical Carcinoma."
- Lead sponsor
- Belgian Gynaecological Oncology Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2014
- Completion date
- October 31, 2023
- Enrollment
- 120 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.